Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial

The Lancet

Volumn 387, Issue 10024, 2016, Pages 1178-1186

  Greenberg, Barry ^a   Butler, Javed ^b   Felker, G Michael ^c   Ponikowski, Piotr ^d   Voors, Adriaan A ^e   Desai, Akshay S ^f   Barnard, Denise ^a   Bouchard, Alain ^g   Jaski, Brian ^h   Lyon, Alexander R ^i,j   Pogoda, Janice M ^k   Rudy, Jeffrey J ^k   Zsebo, Krisztina M ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Cardiology PC   (United States)

^h SHARP MEMORIAL HOSPITAL   (United States)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k Celladon Corporation   (United States)

^l Biovest Consulting   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS 1 VECTOR; PARVOVIRUS VECTOR; PLACEBO; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; CALCIUM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INFUSION; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; VIRAL GENE THERAPY; CLINICAL TRIAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; CALCIUM; DEPENDOVIRUS; DOUBLE-BLIND METHOD; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TREATMENT OUTCOME; UP-REGULATION;

EID: 84961207124     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00082-9     Document Type: Article

References (25)

1. National Heart Lung Blood Institute Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases 2012 US Department of Health and Human Services, National Institutes of Health Bethesda, MD
2. 2+-ATPase in failing and nonfailing human myocardium Circ Res 75 1994 434 442
3. G Hasenfuss, B Pieske Calcium cycling in congestive heart failure J Mol Cell Cardiol 34 2002 951 969
4. C Kho, A Lee, RJ Hajjar Altered sarcoplasmic reticulum calcium cycling - targets for heart failure therapy Nat Rev Cardiol 9 2012 717 733
5. D Eisner, J Caldwell, A Trafford Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later Circ Res 113 2013 958 961
6. M Jessup, B Greenberg, D Mancini et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac diseases (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum CA2+-ATPase in patients with advanced heart failure Circulation 124 2011 304 313
7. K Zsebo, A Yaroshinsky, JJ Rudy et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure. Analysis of recurrent cardiovascular events and mortality Circ Res 114 2014 101 108
8. B Greenberg, A Yaroshinsky, KM Zsebo et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advance heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b) JACC Heart Fail 2 2014 84 92
9. I Karakikes, L Hadri, K Rapti et al. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts Mol Ther 20 2012 565 571
10. D Moher, S Hopewell, KF Schulz et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials BMJ 340 2010 c869
11. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) Guidance for industry: E9 statistical principles for clinical trials 1998 US Department of Health and Human Services, Food and Drug Administration Rockville, MD
12. L Liu, RA Wolfe, X Huang Shared frailty models for recurrent events and a terminal event Biometrics 60 2004 747 756
13. L Liu, X Huang The use of Gaussian quadrature for estimation in frailty proportional hazards models Stat Med 27 2008 2665 2683
14. WB Nelson Recurrent events data analysis for product repairs, disease recurrences, and other applications 2003 Society for Industrial and Applied Mathematics Schenectady, NY
15. CA Beltrami, C Di Loreto, N Finato, SM Yan DNA content in end-stage heart failure Adv Clin Path 1 1997 597 693
16. F del Monte, E Williams, D Lebeche et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum CA2+-ATPase in a rat model of heart failure Circulation 104 2001 1424 1429
17. S Sakata, D Lebeche, N Sakata et al. Restoration of mechanical and energetic function in failing aortic-banded rat hears by gene transfer of calcium cycling proteins J Mol Cell Cardiol 42 2007 852 861
18. Y Kawase, H Ly, F Prunier et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure J Am Coll Cardiol 51 2008 1112 1119
19. M Byrne, J Power, A Preovolos, J Mariani, R Hajjar, D Kaye Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals Gene Ther 15 2008 1550 1557
20. BE Jaski, ML Jessup, DM Mancini et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial J Card Fail 15 2009 171 181
21. JA Mariani, A Smolic, A Preovolos, MJ Byrne, JM Power, DM Kaye Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure Eur J Heart Fail 13 2011 247 253
22. JA Wolfram, JK Donahue Gene therapy to treat cardiovascular disease J Am Heart Assoc 2 2013 e000119
23. F Mingozzi, XM Anguela, G Pavani et al. Overcoming preexisting humoral immunity to AAV using capsid decoys Sci Transl Med 5 2013 194ra92
24. M Urabe, KQ Xin, Y Obara et al. Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression Mol Ther 13 2006 823 828
25. FA Zouein, GW Booz AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling F1000Prime Rep 5 2013 27